Clinical Trials
25 trialsNCT04542824 2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT04224493 2026-06-01
SYMPHONY-1
Ipsen
Phase 3 Active not recruiting
NCT01318317 2026-05-05
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT04712097 2026-05-05
Celestimo
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05888493 2026-04-17
LEDA
Novartis
Phase 3 Active not recruiting
NCT03361852 2026-03-25
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT01479842 2026-03-23
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05025800 2026-03-20
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02446457 2026-03-09
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT03789240 2026-03-03
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05551936 2026-02-17
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT06097364 2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT04680052 2025-12-22
InMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT02390869 2025-12-02
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
Phase 3 Active not recruiting
NCT02180711 2025-10-15
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT05371093 2025-10-15
ZUMA-22
Gilead Sciences
Phase 3 Active not recruiting
NCT04447716 2025-09-15
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
Thomas Jefferson University
Phase 1 Active not recruiting
NCT05788081 2025-08-20
TOP-FLOR
Olivia Newton-John Cancer Research Institute
Phase 2 Active not recruiting
NCT05409066 2025-07-28
EPCORE FL-1
Genmab
Phase 3 Active not recruiting
NCT02889523 2024-10-09
Epi-RCHOP
The Lymphoma Academic Research Organisation
Phase 1/2 Active not recruiting
NCT00877214 2024-08-22
MAINTAIN
University of Giessen
Phase 3 Active not recruiting
NCT03245021 2024-07-30
1stFLOR
Austin Health
Phase 1 Active not recruiting